{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Siebert S"],"funding":["Janssen Research &amp; Development, LLC"],"pubmed_abstract":["<h4>Background</h4>Guselkumab (human monoclonal antibody) selectively inhibits the interleukin (IL)-23p19 subunit.<h4>Objectives</h4>Assess the longer-term pharmacodynamic effects of guselkumab and explore associations between such effects and clinical responses in patients with active psoriatic arthritis (PsA).<h4>Design</h4>DISCOVER-2 randomized 739 biologic-naïve patients with active PsA (swollen/tender joint counts each ⩾5, C-reactive protein (CRP) ⩾0.6 mg/dL) to guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W) or placebo. Guselkumab-randomized participants with available serum biomarker data (randomly selected to reflect demographic and disease characteristics of the DISCOVER-2 population) comprised inflammatory (<i>N</i> = 100) and collagen (<i>N</i> = 178) biom"],"journal":["Therapeutic advances in musculoskeletal disease"],"pagination":["1759720X241283536"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11528637"],"repository":["biostudies-literature"],"pubmed_title":["Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial."],"pmcid":["PMC11528637"],"pubmed_authors":["Rahman P","Guma M","Siebert S","Raychaudhuri SP","Chen W","Chakravarty SD","Schett G","Lavie F","Gao S"],"additional_accession":[]},"is_claimable":false,"name":"Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial.","description":"<h4>Background</h4>Guselkumab (human monoclonal antibody) selectively inhibits the interleukin (IL)-23p19 subunit.<h4>Objectives</h4>Assess the longer-term pharmacodynamic effects of guselkumab and explore associations between such effects and clinical responses in patients with active psoriatic arthritis (PsA).<h4>Design</h4>DISCOVER-2 randomized 739 biologic-naïve patients with active PsA (swollen/tender joint counts each ⩾5, C-reactive protein (CRP) ⩾0.6 mg/dL) to guselkumab (100 mg every 4 weeks (Q4W) or at Weeks 0, 4, and then Q8W) or placebo. Guselkumab-randomized participants with available serum biomarker data (randomly selected to reflect demographic and disease characteristics of the DISCOVER-2 population) comprised inflammatory (<i>N</i> = 100) and collagen (<i>N</i> = 178) biom","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-01T06:52:37.472Z","creation":"2025-04-06T14:23:36.176Z"},"accession":"S-EPMC11528637","cross_references":{"pubmed":["39493888"],"doi":["10.1177/1759720X241283536"]}}